Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease
Tumor necrosis factor (TNF)-alpha plays a critical role in the initiation and progression of Crohn's disease, a chronic inflammatory disorder of the gastrointestinal tract. Infliximab, a chimeric monoclonal antibody blocking TNF-alpha, has proven effective as an induction and maintenance therap...
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 118(2006), 1 vom: 03. Jan., Seite 11-9 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , |
| Format: | Article |
| Langue: | English |
| Publié: |
2006
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Research Support, Non-U.S. Gov't Antibodies, Anti-Idiotypic Antibodies, Blocking Antibodies, Monoclonal Tumor Necrosis Factor-alpha Infliximab B72HH48FLU |